94.85
Merus N V stock is traded at $94.85, with a volume of 2.30M.
It is up +0.51% in the last 24 hours and up +36.32% over the past month.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
See More
Previous Close:
$94.37
Open:
$94.45
24h Volume:
2.30M
Relative Volume:
1.26
Market Cap:
$7.17B
Revenue:
$35.93M
Net Income/Loss:
$-244.56M
P/E Ratio:
-24.01
EPS:
-3.95
Net Cash Flow:
$-157.31M
1W Performance:
+0.62%
1M Performance:
+36.32%
6M Performance:
+125.99%
1Y Performance:
+77.62%
Merus N V Stock (MRUS) Company Profile
Name
Merus N V
Sector
Industry
Phone
31 030 253 8800
Address
YALELAAN 62, 3584 CM UTRECHT
Compare MRUS with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
MRUS
Merus N V
|
94.85 | 7.15B | 35.93M | -244.56M | -157.31M | -3.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
![]()
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
![]()
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Merus N V Stock (MRUS) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Sep-17-25 | Initiated | Barclays | Overweight |
Aug-25-25 | Initiated | Alliance Global Partners | Buy |
Feb-13-25 | Initiated | Piper Sandler | Overweight |
Feb-07-25 | Initiated | Wells Fargo | Overweight |
Nov-21-24 | Initiated | Goldman | Buy |
Oct-24-24 | Initiated | UBS | Buy |
Mar-28-24 | Initiated | Truist | Buy |
Mar-04-24 | Reiterated | Needham | Buy |
Nov-02-23 | Initiated | Canaccord Genuity | Buy |
Aug-21-23 | Initiated | TD Cowen | Outperform |
Aug-02-22 | Initiated | Stifel | Buy |
Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
Feb-10-22 | Initiated | Needham | Buy |
Nov-17-21 | Resumed | Guggenheim | Buy |
Jun-07-21 | Upgrade | Citigroup | Neutral → Buy |
Apr-08-21 | Initiated | William Blair | Outperform |
Mar-16-21 | Initiated | SVB Leerink | Outperform |
Jun-26-20 | Initiated | H.C. Wainwright | Buy |
May-27-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Nov-20-19 | Resumed | Guggenheim | Buy |
Jun-28-19 | Initiated | ROTH Capital | Buy |
Apr-12-19 | Resumed | Guggenheim | Buy |
Apr-03-19 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
Mar-27-19 | Initiated | Berenberg | Buy |
Jan-02-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
Mar-21-17 | Downgrade | Citigroup | Buy → Neutral |
Dec-22-16 | Upgrade | Citigroup | Neutral → Buy |
Nov-07-16 | Downgrade | Citigroup | Buy → Neutral |
Jun-13-16 | Initiated | Citigroup | Buy |
Jun-13-16 | Initiated | Guggenheim | Buy |
Jun-13-16 | Initiated | Wedbush | Outperform |
View All
Merus N V Stock (MRUS) Latest News
Merus to present petosemtamab data for colorectal cancer at conference By Investing.com - Investing.com South Africa
Merus N.V. to Present Two Abstracts on Petosemtamab at AACR-NCI-EORTC Conference in Boston - Quiver Quantitative
Merus Announces Petosemtamab in Metastatic Colorectal - GlobeNewswire
Phase 2 interim data: Merus' petosemtamab to be presented in plenary at AACR Oct 24; poster on cancer stem cells - Stock Titan
Will Merus N.V. outperform the market2025 Trading Recap & High Accuracy Trade Signal Alerts - newser.com
Will Merus N.V. stock deliver better than expected guidance2025 Macro Impact & Technical Confirmation Alerts - newser.com
Can you recover from losses in Merus N.V.Trade Entry Report & Free Low Drawdown Momentum Trade Ideas - newser.com
Why Merus N.V. is moving today2025 Big Picture & Breakout Confirmation Trade Signals - newser.com
Can Merus N.V. stock double in next 5 yearsTrade Exit Summary & Stepwise Trade Signal Implementation - newser.com
Will Merus N.V. stock sustain high P E ratiosJuly 2025 Weekly Recap & Weekly High Potential Alerts - newser.com
Deals In Depth: September 2025 - insights.citeline.com
Merus N.V. announces proposed public offering of common shares - MSN
Innate Pharma and Merus gets FDA Breakthrough Therapy Designation for their respective treatments - MSN
Merus (NASDAQ:MRUS) Hits New 12-Month HighHere's Why - MarketBeat
Merus (NASDAQ:MRUS) Earns Sell (D-) Rating from Weiss Ratings - MarketBeat
Automated trading signals detected on Merus N.V.July 2025 Outlook & Low Risk High Win Rate Picks - newser.com
Is Merus N.V. (2GH) stock safe for risk averse investorsWall Street Watch & Accurate Entry/Exit Alerts - newser.com
What margin trends mean for Merus N.V. stockNew Guidance & Daily Price Action Insights - newser.com
Is Merus NV a good long term investmentTrading Psychology Tips & Market Monitoring and Alerts - earlytimes.in
SHAREHOLDER RIGHTS ALERT: Halper Sadeh LLC Investigates PINC, ODP, PRO, MRUS on Behalf of Shareholders - GlobeNewswire Inc.
Merus NV stock hits all-time high at 94.56 USD By Investing.com - Investing.com Nigeria
Merus NV stock hits all-time high at 94.56 USD - Investing.com
Will Merus N.V. stock see PE expansion2025 Short Interest & Real-Time Volume Spike Alerts - newser.com
Why Merus N.V. (2GH) stock could outperform next yearJuly 2025 Movers & Reliable Entry Point Alerts - newser.com
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise - Investing.com Nigeria
Merus’s SWOT analysis: oncology biotech stock faces acquisition, pipeline promise By Investing.com - Investing.com South Africa
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of - GlobeNewswire
Oklahoma City NewsThe Oklahoman - FinancialContent
Merus (NASDAQ:MRUS) Downgraded by Leerink Partnrs to "Hold" - MarketBeat
GMAB Stock Soars 21.9% in a Month Following MRUS Acquisition Deal - sharewise.com
Truist Securities raises Genmab stock price target to $49 on Merus acquisition - Investing.com
Is Merus N.V. building a consolidation baseQuarterly Profit Review & Short-Term High Return Strategies - newser.com
Leerink Partners Downgrades Merus to Market Perform From Outperform, Adjusts PT to $97 From $95 - MarketScreener
MRUS Downgraded to Market Perform by Leerink Partners with Raise - GuruFocus
What MACD signals say about Merus N.V.Profit Target & Consistent Profit Alerts - newser.com
Leerink Partners downgrades Merus stock to Market Perform on Genmab deal - Investing.com
What’s the recovery path for long term holders of Merus N.V.2025 Major Catalysts & Reliable Entry Point Trade Alerts - newser.com
How big funds are accumulating Merus N.V. (2GH) stockRecession Risk & Verified Entry Point Detection - newser.com
Relative strength of Merus N.V. in sector analysisJuly 2025 Recap & Fast Entry Momentum Alerts - newser.com
Will Merus N.V. (2GH) stock maintain strong growth2025 Institutional Moves & Community Verified Swing Trade Signals - newser.com
Genmab Agrees to Buy Cancer Drugmaker Merus for $8 Billion - MSN
Genmab acquires Merus for $97 per share in cash or $8B - MSN
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRU - GuruFocus
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates EA, MRUS, VECO on Behalf of Shareholders - cnhinews.com
Truist raises Genmab stock price target to $49 on Merus acquisition - Investing.com
Custom strategy builders for tracking Merus N.V.Market Sentiment Summary & Daily Profit Focused Screening - newser.com
Will Merus N.V. stock continue upward momentum2025 Big Picture & Technical Entry and Exit Alerts - newser.com
Merus N V Stock (MRUS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Merus N V Stock (MRUS) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
Silverman Peter B. | COO & GC |
Jul 17 '25 |
Sale |
60.00 |
25,000 |
1,500,000 |
0 |
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):